Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GI pharm > Cancer drugs > Flashcards

Cancer drugs Flashcards

1
Q

Bevacizumab

Cancers treated:

MOA:

Issues

A

Colorectal

MOA: rhuMAB-VEGF

issues: BBW: Bleeding, GI performation, wound dehisence

ADE: HTN, hypersensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Capecitabine

cancer?

MOA?

Issues

A

colorectal

MOA: oral produrug metabolized to 5FU

Issues: BBW: dihydropyrimidine dehydrogenase (DPD) deficiency(familial pyrimidinemia) prevents metabolic activation. C/I in renal dysfunction; adverse CV events, Neurologic and hematologic tox

ADE: interacts with oral anticoagulant, coumarin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Cetuximab

cancer:

MOA:

Issues

A

cancer: colorectal

MOA: rh/mMAB-EGFR

Issues: BBW: caridac and respiratory arrest, +/- sudden death

ADE: infusion reactions. acneiform rash common (76-88%), severe in up to 17% of patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

**Cisplatin **

cancers(3)

MOA

Issues

A

cancers: anal, esophageal, gastric

MOA: forms DNA intrastand crosslinks and adducts

Issues:

  1. BM suppression and platinum hypersensitivity
  2. hearing impairment and renal failure/impairment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

**Docetaxel **

Cancer

MOA

Issues

A

Cancer: Esophageal, gastric

MOA: microtubule stabilizer inhibiitng depolymerization

Issues: **BBW: Increases tx related mortality in NSCLC; edema, C/I in hepatic disease **

ADE: neutropenia = dose limiting tox

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Doxorubicin

cancer(s)

MOA

Issues

A

cancers: gastric and liver

MOA: intercalator, free radical generator, topo II inhibitor (dexrazoxane - reduces cardio tox of doxo via decreased free radical formation)

BBW: ** 1. BW suppression and heart disease**

**2. hepatic disease **

**3. secondary malignancies and extravasational necrosis **

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Erlotinib (No BBW)

cancer

MOA

Issues

A

cancer: pancreas

MOA: EGFR-TKI

ADE: 1. GI tox: N/V diarrhea

  1. prolonged bleeding
  2. elevated LFTS
  3. ocular tox and rarely interstitial lung disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

**Fluorouracil **

cancers

MOA

issues

A

cancers: esophageal, gastric, pancreas and liver, colorectal and anal

MOA: pyrimidine antimetabolite that inhibits thymidylate synthase (TS) and interferes with RNA synthesis and function. also some effects on DNA

BBW: **Dihyropyrimidien dehydrogenage(DPD) deficiency (familiar pyrimidinemia) lead to enhanced neurotox; enzyme necessary for degrading fluorouracil to an inactive compound (enzyme needed for degrading fluorouracil to an inactive compund) **

ADE: severe hematological tox incluidng BM suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

**Gemcitabine **

cancer

MOA

issues

A

cancer: pancrease

MOA: DNA polymerase inhibitor via incorporation of triphosphate form during DNA synthesis

ADE: 1. BM suppression and infection

  1. sensory peripheral neuropathy, arhtralgia, drowsiness, and fatigue
  2. N/V, diarrhea, anorexia commonplace - resolve in 2-3 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

glutamic acid

cancer

MOA

issues

A

cancer: gastric

MOA: nutritional supplement; used to counterbalance deficiencies of HCl in gastric juice

issues: taken orally before meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

**imatinib **

cancer

MOA

issues

A

cancer: GIST only

MOA: oral TKI as adjuvant tx following complete resection of Kit (CD1117) positive GIST

ADE: 1.GI tox (pain, bloating, N/V, constipation, stomatitis, dyspepsia, etc) common.

  1. CHF reported in some pts.
  2. neurologic tox
  3. fluid retention and edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

interferon-alpha

Cancer

MOA

ISSUES

A

cancer: GI carcinoid

MOA: enzyme activation follwoing cell surface receptor binding and tyrosine kinase activation

BBW: Neuropsychiatric events: aggression, deppression, and suicice

ADE: flu-like sympotms: fatigue, fever, malaise, myalgia, arthralgia, chills, headache, and weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

**irinotecan **

cancer

MOA

issues

A

cancer(s): colorectal, gastric, pancreas

MOA: Topo I inhibitor

**BBW: BM suppression, diarrhea **

ADE: asthenia, fever, pain, weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Leucovorin

cancers

MOA

issues

A

cancers: colorectal and pancrease

MOA: redcued folate; modulates the effects of 5-FU

Issues: diarrhea and dehydration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

**Methysergide **

not for cancers

MOA

issues

A

MOA: serotonin inhibitor in GI tract

ADE: vasoconstrictor of large and small arteries; used for migraine therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

mitomycin

cancer:

MOA

issues (all BBWs)

A

cancer: anal cancer

MOA: mono or bifunctional alkylating agen

BBW(4): **BM suppression, thrombocytopenia, leukopenia, hemolytic-uremic syndrome(microangiopathic hemolytic anemia, thrombocytopenia/irreversible renal failure) , **

17
Q

**octreotide **

cancer

MOA

issues

A

cancer: GI carcinoid

MOA: somatostatin analong:

  1. reduces duodenal bicarbonate, amylase,
  2. reduces gastric acidity
  3. inhibits gallbladder contractility and bile secretion, 4.inhibits meal-induced increases in SMA and portal venous blood

ADE: monitor blood glucose, inhibits insulin and glucagon. dose-related diarrhea

18
Q

oxaliplatin

cancer

MOA

issues (5)

A

cancers: colorectal, pancrease

MOA: more potent than cisplatin. the **1,2 diaminocyclohexane **carrier though to contribute to enchanced **cytotoxicty and lack of cross-resistance btw oxaliplatin and cisplatin **

**BBW: dose-limiting neurotoxicity. **

ADE: thrombocytopenia if used with 5-FU + leucovorin. Diarrhea, N/V, stomatitis

19
Q

sorafenib

cancer

MOA

Issues

A

cancer(s): liver

MOA: oral multi-kinase inibitor targeting serine/threonine and receptor tyrosine kinase in both tumor and vasculature.

targeted kinases: Raf, VEGFR2,3, PDGFR-beta, KIT, FLT-3, RET

ADE: hand-foot skin rxn characterized by redness, pain, swelling, or blisters onthe palms of the hands/soles of the feet. appears in first 6weeks of tx.

20
Q

sunitinib

cancer

MOA

ADE

A

cancer: GIST

MOA: inhibitor of >80 receptor tyrosine kinase(RTKs) including: PDGFRalpha, beta, VEGFR1,2,3, stem cell factor receptor KIT, FLT-3, CSR-1R, and RET

ADE: thrombocytopenia and bleeidng, QT prolongation (fatal) GI complications: GI perforation (have occured rarely in pt w/intraabdominal malignancies)

21
Q

Trastuzumab

cancer:

MOA

issues

A

cancer: gastric

MOA: HER-2/neu anitbody; HER2 is downregulated, cyclin-dependent kinase inhibitor p27 accumulates, and cell cycle arrest occurs. also inhibits constitutive HER2 cleavage/shedding mediated by metalloproteases which may correlate with clinical activity.

ADE: LVEF dysfunction and cardiomyopathy. severe infusion related rxns including: anaphylaxis, angioedema, and pulmonary tox; pulmonary tox worse in pts with intrinsic lung disease: **COPD, asthma, resp insufficiency **

GI pharm (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions